Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,195.60 -25.02 (-0.13%) FTSE 100
8,361.95 -54.50 (-0.65%) Bitcoin USD
69,562.43 -1,011.08 (-1.43%) CMC Crypto 200
1,509.94 -16.47 (-1.08%)
BIIB Jan 2025 305.000 call
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.2500 |
| Ask | 4.8000 |
| Strike | 305.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 63 |
ReutersBiogen in up to $1.8 billion deal as rare diseases take center stage
Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ. The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.
GlobeNewswireBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Bioscience
ZacksWhy Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
